- Myovant Sciences press release ( NYSE: MYOV ): Q2 GAAP EPS of -$0.47 beats by $0.02 .
- Revenue of $104.8M (+34.5% Y/Y) beats by $11.33M .
- Cash, cash equivalents, marketable securities, and amounts available under the Sumitomo Pharma Loan Agreement totaled $412.6 million in the aggregate as of September 30, 2022, and consisted of $371.3 million of cash, cash equivalents, and marketable securities and $41.3 million of available borrowing capacity under the Sumitomo Pharma Loan Agreement.
For further details see:
Myovant Sciences GAAP EPS of -$0.47 beats by $0.02, revenue of $104.8M beats by $11.33M